Cardiac surgery with cardiopulmonary bypass: Does aprotinin affect outcome?

British Journal of Anaesthesia

Volumn 99, Issue 5, 2007, Pages 646-652

  Van Der Linden, P J ^a   Hardy, J F ^b   Daper, A ^c   Trenchant, A ^c   De Hert, S G ^d  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anaesthesia, cardiac; Aprotinin; Blood, loss; Outcome; Surgery, cardiac

Indexed keywords

APROTININ; CREATININE; SERINE PROTEINASE INHIBITOR;

ABDOMINAL DISEASE; ABDOMINAL INFECTION; ADULT; AGED; AGING; ARTICLE; BLOOD CONSERVATION; BLOOD TRANSFUSION; CALCULATION; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMA; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY SURGERY; EUROSCORE; FEMALE; FORWARD HEART FAILURE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REOPERATION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SURGICAL MORTALITY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; AGE; BLEEDING; DRUG SCREENING; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME;

EID: 38349180312     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem252     Document Type: Article

References (39)

1. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74: 1180-6
2. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34: 1608-16
3. Mortimer PP. Making blood safer. Br Med J 2002; 325: 400-1
4. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; CD001886
5. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-8
6. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7
7. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials 2005; 2: 218-32
8. Mangano DT, Tudor JC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65
9. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006; 46: 327-38
10. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471-9
11. Sedrakyan A, Atkins D, Treasure T. The risk of aprotinin: a conflict of evidence. Lancet 2006; 367: 1376-7
12. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-91
13. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004; 101: 9-20
14. Van der Linden P, De Hert S, Daper A, et al. A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery. Can J Anaesth 2001; 48: 894-901
15. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undegoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271-9
16. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997; 95: 878-84
17. Green SB. How many subjects does it take to do a regression analysis? Multivariate Behav Res 1991; 26: 499-510
18. Cohen J. A power primer. Psychol Bull 1992; 112: 155-9
19. Sedrakyan A, Atkins D, Treasure T. The risk of aprotinin: a conflict of evidence. Lancet 2006; 367: 1376-7
20. Body SC, Mazer CD. Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth Analg 2006; 103: 1354-9
21. Royston D, Van Haaften N, De Vooght P. Aprotinin; friend or foe? A review of recent medical literature. Eur J Anaesthesiol 2007; 24: 6-14
22. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-8
23. Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24
24. Saffitz JE, Stahl DJ, Sundt TM, Wareing TH, Kouchoukops NT. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest. Am J Cardiol 1993; 72: 1080-2
25. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-53
26. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the Internatonial Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-30
27. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-67
28. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995; 59: 132-6
29. Vio CP, Oestreicher E, Olivarria V, Velarde V, Mayfield RK, Jaffa AA. Cellular distribution of exogenous aprotinin in the rat kidney. Biol Chem 1998; 379: 1271-7
30. Rustom R, Grime S, Maltby P, Stockdale HR, Critchley M, Bone JM. A new method to measure renal tubular degradation of small filtered proteins in man using radiolabelled aprotinin (Trasylol). Clin Sci 1992; 82: 289-94
31. Karkouti K, Beattie WS, Wijeysundera DN, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 2005; 129: 391-400
32. Provenchere S, Plantefeve G, Hufnagel G, et al. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. Anesth Analg 2003; 96: 1258-64
33. Bove T, Calabro MG, Landoni G, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 442-5
34. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006; 103: 1074-81
35. Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJF, O'Donnell AP, Shorten GD. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized control study. Can J Anaesth 2004; 51: 1002-9
36. Royston D, Levy JH, Fitch J, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006; 103: 1082-8
37. Van der Linden P, Dierick A. Blood conservation strategies in cardiac surgery. Vox Sang 2007; 92: 103-12
38. Foster EM. Propensity score matching: an illustrative analysis of dose response. Med Care 2003; 41: 1183-92
39. Roques F, Nashef SAM, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothor Surg 1999; 15: 816-23